Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference

Novo Nordisk CEO Maziar Mike Doustdar shakes hands with U.S. President Donald Trump during an event to announce a deal with Eli Lilly and Novo Nordisk to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White House in Washington, D.C., U.S., November 6, 2025.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Good morning from San Francis ...